CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations

Why It Matters

Including Trulicity shows Medicare’s price‑negotiation program is extending to fast‑growing GLP‑1 drugs, potentially reshaping market pricing and delivering savings to seniors.

Key Takeaways

• CMS includes Trulicity in third Medicare price negotiation round
• Gilead's Biktarvy also selected for negotiations
• Negotiations stem from Inflation Reduction Act's drug pricing provisions
• Potential rebates could lower out‑of‑pocket costs for seniors
• Companies may face reduced revenues and pricing strategy shifts

Pulse Analysis

The Inflation Reduction Act gave Medicare a powerful new lever: the ability to negotiate drug prices for a select list of high‑cost medicines. In its third negotiation cycle, the Centers for Medicare & Medicaid Services (CMS) added Eli Lilly’s once‑weekly GLP‑1 agonist Trulicity and Gilead’s HIV combination Biktarvy to the roster. By targeting these specialty drugs, the program seeks to rein in the rapid escalation of pharmacy spend that has strained federal budgets and driven up premiums for beneficiaries.

Trulicity’s entry into the negotiation pool is especially noteworthy because GLP‑1 therapies have become a blockbuster segment, with sales soaring as they are prescribed for diabetes and weight management. The inclusion signals that Medicare will not limit itself to traditional high‑price drugs but will also address newer, high‑volume classes. Manufacturers may need to adjust pricing strategies, consider earlier discounts, or accelerate pipeline diversification to protect margins. The outcome of these talks could set a pricing precedent that influences contracts with private insurers and pharmacy benefit managers.

For patients, the negotiations promise lower out‑of‑pocket expenses if rebates translate into reduced copays. However, there is a risk that manufacturers could respond by limiting drug availability or shifting costs elsewhere. The broader healthcare system will watch closely as the third‑round results shape future cycles, potentially expanding the negotiation list to more GLP‑1 agents and other specialty treatments, thereby amplifying the Act’s impact on national drug spending.